北美心血管代谢疾病市场预测至 2028 年 - COVID-19 影响和按类型（心血管疾病 (CVD)、2 型糖尿病、高血压和肥胖）、治疗（ACE 抑制剂、利尿剂、格华止等）、剂量（片剂和注射剂）、给药途径（口服和静脉注射）、最终用户（医院、诊所和家庭护理机构）和分销渠道（医院药房、零售药房和在线药房）
市场介绍
心脏代谢疾病的特点是一组异常和症状，这些异常和症状会引起个人患心血管疾病的风险。高血压、肥胖、胰岛素抵抗、血脂异常、胆固醇水平 (LDL) 不良和葡萄糖耐量是其中一些症状。患有心脏代谢综合征的人容易患上其他几种危及生命的疾病，例如 2 型糖尿病、中风、冠状动脉疾病 (CAD)、心血管疾病 (CVD) 等。
此外，心脏代谢疾病的日益流行预计将推动预测期内的市场增长。然而，低收入和中等收入国家 (LMIC) 对 CVD 的诊断不足限制了北美心脏代谢疾病市场的增长。
COVID-19 的影响持续激增，由此给医疗系统带来的负担扰乱了经济、医疗保健系统和正在进行的临床试验。 COVID-19 大流行还引发了心血管疾病的发作或加剧。此外，COVID-19 正在引发严重的心理健康问题，抑郁症与心血管疾病之间的关联早已被报道。根据克利夫兰诊所的数据，大约 15% 的 CVD 患者和高达 20% 的接受冠状动脉搭桥手术的患者会出现严重抑郁症。即使是轻度抑郁，例如情绪低落，也会增加患冠状动脉疾病的相对风险。 COVID-19 大流行期间采取的限制性措施可能会增加心血管疾病患者的抑郁症。此外，许多公司报告美国心血管疾病和糖尿病药物的销量下降。例如，2020年第四季度，由于美国甘精胰岛素平均价格持续下降以及COVID-19环境的一些影响，赛诺菲的全球糖尿病销售额下降了8.4%。此外，心血管产品销售额下降了 7.1%，部分原因是由于 COVID-19 环境。
市场概览和动态
北美心脏代谢疾病市场预计将从 2021 年的 329.121 亿美元增至 2028 年的 435.836 亿美元；预计 2021 年至 2028 年复合年增长率为 4.1%。人工智能的整合进一步为全球心脏代谢疾病市场的增长提供了利润丰厚的机会，预计将在预测期内继续支持该市场。 2021 年 6 月，ACC 和 GE Healthcare 通过 ACC 应用健康创新联盟 (AHIC) 的支持和参与进行合作，为心脏病学领域的人工智能和数字技术制定路线图，并制定改善健康结果的新战略。
主要细分市场
从类型来看，心血管疾病细分市场占2020年北美心脏代谢疾病市场份额最大。就治疗而言，ACE抑制剂细分市场占据2020年北美心脏代谢疾病市场最大份额。就剂量而言，片剂细分市场占比最大2020年北美心脏代谢疾病市场份额。从给药途径来看，2020年北美心脏代谢疾病市场中口服细分市场份额最大。从最终用户来看，医院细分市场份额最大2020 年北美心脏代谢疾病市场的份额。此外，从分销渠道来看，医院药房细分市场在 2020 年占据最大的市场份额。
主要来源和上市公司
准备本心脏代谢疾病报告时参考的一些主要一手和二手来源北美市场包括公司网站、年度报告、财务报告、国家政府文件、统计数据库等。报告中列出的主要公司包括礼来公司、拜耳公司、Arrowhead Pharmaceuticals, Inc.、诺华公司、勃林格殷格翰国际有限公司、诺和诺德公司、阿斯利康、Alnylam Pharmaceuticals, Inc.、Cardax, Inc.和Kowa Company, Ltd.
购买理由报告
- 了解北美心脏代谢疾病市场格局并确定可能保证丰厚回报的细分市场
- 了解不断变化的市场格局并在竞争中保持领先
- 通过识别细分市场，有效规划北美心脏代谢疾病市场的并购和合作交易拥有最有前景的销售机会
- 通过对各个细分市场的市场表现进行敏锐而全面的分析，做出明智的业务决策
- 获得2021年-2028年基于各个细分市场的北美心脏代谢疾病市场的市场收入预测
北美心脏代谢疾病市场细分
按类型
- 心血管疾病（CVD）
- 2 型糖尿病
- 高血压
- 肥胖
治疗
- ACE抑制剂
- 利尿剂
- 格华止
- 其他
按剂量
- 片剂
- 注射剂
按给药途径
- 口服
- 静脉注射
最终用户
- 医院
- 诊所
- 家庭护理环境
- 医院药房
- 零售药房
- 在线药房
按国家/地区
- 北美
- 美国
- 加拿大
- 墨西哥
提及的公司
- 礼来公司。
- 拜耳股份公司
- Arrowhead Pharmaceuticals, Inc
- 诺华公司 ;
- 勃林格殷格翰国际有限公司
- 诺和诺德公司
- 阿斯利康
- Alnylam Pharmaceuticals, Inc.
- Cardax, Inc.
- 兴和株式会社
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 North America Cardiometabolic Diseases market – By Country
2. North America Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. North America Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. North America Cardiometabolic Diseases Market – Regional Analysis
6.1 North America Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. North America Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. North America Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. North America Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. North America Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. North America Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. North America Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. North America Cardiometabolic Diseases Market – Geographic Analysis
13.1 North America: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 North America: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.1.3 North America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.4 North America Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.5 North America Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.6 North America Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.7 North America Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
13.1.8 North America Cardiometabolic Diseases Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Million)
13.1.9 North America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 US: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.1 US: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.2 US Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.3 US: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.4 US: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.5 US: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)
13.1.9.1.6 US: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.7 US: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.9.2 Canada: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.1 Canada: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.2 Canada: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.3 Canada: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.4 Canada: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.5 Canada: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)
13.1.9.2.6 Canada: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.7 Canada: Cardiometabolic Diseases Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Million)
13.1.9.3 Mexico: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.1 Mexico: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.2 Mexico: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.3 Mexico: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.4 Mexico: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.5 Mexico: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)
13.1.9.3.6 Mexico: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.7 Mexico: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on North America Cardiometabolic Diseases Market
14.1 North America: Impact Assessment of COVID-19 Pandemic
15. North America Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Eli Lilly and Company.
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Bayer AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Arrowhead Pharmaceuticals, Inc
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novartis AG
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 Boehringer Ingelheim International GmbH
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 Novo Nordisk A/S
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 AstraZeneca
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Products and Services
16.7.4 Financial Overview
16.7.5 SWOT Analysis
16.7.6 Key Developments
16.8 Alnylam Pharmaceuticals, Inc.
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
16.9 Cardax, Inc.
16.9.1 Key Facts
16.9.2 Business Description
16.9.3 Products and Services
16.9.4 Financial Overview
16.9.5 SWOT Analysis
16.9.6 Key Developments
16.10 Kowa Company, Ltd.
16.10.1 Key Facts
16.10.2 Business Description
16.10.3 Products and Services
16.10.4 Financial Overview
16.10.5 SWOT Analysis
16.10.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. North America Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 3. North America Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 4. North America Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 5. North America Cardiometabolic Diseases Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 6. North America Cardiometabolic Diseases Market, by Distribution Channel- Revenue and Forecast to 2028 (USD Million)
Table 7. US Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. US Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 9. US Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 10. US Cardiometabolic Diseases Market, by Route of Administration- Revenue and Forecast to 2028 (USD Million)
Table 11. US Cardiometabolic Diseases Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 12. US Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 13. Canada: Cardiometabolic Diseases Market, by Type -Revenue and Forecast to 2028 (USD Million)
Table 14. Canada: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 15. Canada: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. Canada: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)
Table 17. Canada: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 18. Canada: Cardiometabolic Diseases Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Million)
Table 19. Mexico Cardiometabolic Diseases Market, by Type -Revenue and Forecast to 2028 (USD Million)
Table 20. Mexico Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 21. Mexico Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. Mexico Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)
Table 23. Mexico Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 24. Mexico Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 25. Organic Developments in the Cardiometabolic Diseases Market
Table 26. Inorganic Developments in the Cardiometabolic Diseases Market
Table 27. Glossary of Terms, North America Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. North America Cardiometabolic Diseases Market Segmentation
Figure 2. North America Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share Type of North America Cardiometabolic Diseases Market
Figure 4. North America Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. North America Cardiometabolic Diseases Market, Industry Landscape
Figure 6. North America PEST Analysis
Figure 7. North America Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. North America Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. North America: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. North America Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)
Figure 35. North America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 36. US: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 37. Canada: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. Mexico: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. Impact of COVID-19 Pandemic on North America Cardiometabolic Diseases Market
Figure 40. Growth Strategies in the Cardiometabolic Diseases Market (%)
S
- Eli Lilly and Company.
- Bayer AG
- Arrowhead Pharmaceuticals, Inc
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Cardax, Inc.
- Kowa Company, Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.